Connection
Bradley Dixon to Complement C5
This is a "connection" page, showing publications Bradley Dixon has written about Complement C5.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.042 |
|
|
|
-
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2021 07; 100(1):225-237.
Score: 0.042